+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients



Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients



European Respiratory Journal 44(4): 951-962



Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with chronic inflammation but the pathological mechanisms are largely unknown. Our study aimed to simultaneously profile a broad range of cytokines in the supernatant of pulmonary endarterectomy (PEA) surgical material, as well as prospectively in patients with CTEPH to investigate whether circulating cytokines are associated with haemodynamic and physical characteristics of CTEPH patients. Herein, we show that PEA specimens revealed a significant upregulation of interleukin (IL)-6, monocyte chemoattractant protein-1, interferon-γ-induced protein-10 (IP)-10, macrophage inflammatory protein (MIP)1α and RANTES compared to lung tissue from healthy controls. In prospectively collected serum, levels of IL-6, IL-8, IP-10, monokine induced by interferon-γ (MIG) and MIP1α were significantly elevated in CTEPH patients compared to age- and sex-matched healthy controls. In serum of idiopathic pulmonary arterial hypertension (IPAH) patients, only IP-10 and MIG were significantly increased. In CTEPH but not in IPAH, IP-10 was negatively correlated with cardiac index, 6-min walking distance and carbon monoxide diffusion capacity. In vitro, IP-10 significantly increased migration of freshly isolated adventitial fibroblasts. Our study is the first to show that IP-10 secretion is associated with poor pulmonary haemodynamics and physical capacity in CTEPH and might be involved in the pathological mechanism of PEA tissue formation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269808

Download citation: RISBibTeXText

PMID: 25034560

DOI: 10.1183/09031936.00145013


Related references

Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Medical Weekly 137(41-42): 573-580, 2007

The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis 42(1): 38-45, 2017

Growing number of incident pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Latvia: a shifting epidemiological landscape? Data from a national pulmonary hypertension registry. European Journal of Internal Medicine 2018, 2018

Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology 2019, 2019

Balloon pulmonary angioplasty for the treatment of residual pulmonary hypertension after pulmonary endoarterectomy in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Journal of Vascular and Interventional Radiology 27(3): S289-S290, 2016

Intraoperative 3-Dimensional Echocardiography-Derived Right Ventricular Volumetric Analysis in Chronic Thromboembolic Pulmonary Hypertension Patients Before and After Pulmonary Thromboendarterectomy. Journal of Cardiothoracic and Vascular Anesthesia 2018, 2018

Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. Journal of Cardiovascular Medicine 2019, 2019

Clinical analysis in seventy-two patients with chronic thromboembolic pulmonary hypertension. Zhonghua Nei Ke Za Zhi 36(5): 321-324, 1997

Vessel Stretching Is a Cause of Lumen Enlargement Immediately After Balloon Pulmonary Angioplasty: Intravascular Ultrasound Analysis in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation. Cardiovascular Interventions 11(4): E006010, 2018

An Analysis of Pulmonary Arterial Hypertension Targeted Medication Before and After Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. Chest Journal 148(4): 1002a-1002b, 2015

Predictors of residual pulmonary hypertension after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. International Journal of Cardiology 226: 118-120, 2016

Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis. Clinical Respiratory Journal 12(6): 2065-2074, 2018

Wave Intensity Analysis Provides Novel Insights Into Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association 6(11), 2018

Longitudinal analysis of perfusion lung scintigrams of patients with unoperated chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis 92(1): 201-207, 2004

High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension. Plos One 11(1): E0147396, 2016